Novartis’ Experimental Heart Drug Pelacarsen Falls Short in Major Trial

Novartis revealed on Friday that its investigational medication pelacarsen, once viewed as a potential breakthrough for averting heart attacks, strokes, and cardiovascular fatalities, did not meet expectations.

The statement offered no additional information, yet it sent ripples of surprise through the cardiology community.

“Oh no — oh no,” remarked Dr. David Maron, president of the American Society for Preventive Cardiology. “This is a substantial setback; I’m at a loss for words.”

Dr. Harlan Krumholz, a cardiologist at Yale, exclaimed, “This is deeply disappointing news. We had all been anticipating a reason to celebrate.”

The medication targets lipoprotein(a), a protein strongly linked to heart disease risk. Prior observational studies suggested that reducing Lp(a) levels would shield individuals from developing the condition.

Many cardiologists believed that Lp(a)-lowering therapies could fill a critical gap in preventing heart attacks among individuals who already manage cholesterol, blood pressure, avoid smoking, exercise regularly, and maintain a healthy weight. They hoped these drugs might eventually rival the impact of statins.

“How much has Novartis invested over the past two years in promoting Lp(a) therapy?” Dr. Krumholz asked, still expressing his disbelief.

Amgen and Eli Lilly are also developing comparable agents and conducting large-scale trials, prompting scrutiny of the broader Lp(a) hypothesis.

The Novartis trial spanned seven years and enrolled 8,323 participants with elevated Lp(a) and existing heart disease. Subjects received monthly injections of either the drug or a placebo via a pre‑filled syringe, similar to the administration route for certain obesity medications.

Approximately one in five individuals exhibit elevated Lp(a) levels, translating to an estimated 1.4 to 2 billion people worldwide.

Individuals with Lp(a) concentrations exceeding 250 nanograms per deciliter—about 10 % of the global populace—face roughly double the risk of heart attack or stroke. Even modestly elevated levels raise risk by about 25 %.

Unlike cholesterol, which responds to diet and weight, Lp(a) levels are genetically fixed and remain unaffected by lifestyle modifications, staying constant over a person’s lifetime.

An earlier investigation showed that the Novartis agent lowered Lp(a) by roughly 80 %, leading many to anticipate that it would effectively prevent heart attacks and strokes.

In accordance with federal disclosure rules, Novartis reported the trial’s unsuccessful outcome, noting that results influencing stock prices must be made public. The full dataset is slated for presentation in November at the American Heart Association’s annual meeting, alongside a manuscript destined for a top‑tier medical journal.

Dr. Krumholz offered a cautionary note: strong associations observed in studies do not establish causation. What appears to drive heart disease may merely be a biomarker, much as wrinkles signal aging without causing it.

Cardiologists have encountered similar disappointments before; in August, they were startled when an anti‑inflammatory agent failed to curb heart disease risk.

For years, boosting HDL—often dubbed “good” cholesterol—was thought to shield against heart disease. The experimental drug torcetrapib generated optimism, yet its large trial ended in failure, actually raising risk. Subsequent research revealed that high HDL serves as a marker of lower risk rather than a causal factor.

According to Dr. Krumholz, Pfizer’s CEO once believed that the company’s future hinged on the success of this medication.

Just two days prior to learning of the trial’s failure, Pfizer informed the FDA of its intent to seek marketing approval for the drug.

Nevertheless, the Lp(a) hypothesis may still hold promise; ongoing large trials by Amgen and Eli Lilly could yet demonstrate a benefit from lowering Lp(a).

Dr. Krumholz added, “This result prompts us to question whether pursuing this avenue remains worthwhile.”

Source link